BriaCell Therapeutics Stock (NASDAQ:BCTX)
Previous Close
$0.70
52W Range
$0.52 - $7.18
50D Avg
$0.79
200D Avg
$2.58
Market Cap
$13.33M
Avg Vol (3M)
$366.21K
Beta
1.74
Div Yield
-
BCTX Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BCTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PDSB | PDS Biotechnology Corporation |
| HOOK | HOOKIPA Pharma Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| ELEV | Elevation Oncology, Inc. |